Personal information

Other IDs

Loop profile: 108134
Scopus Author ID: 12775977300

Keywords

gene therapy, gene editing, CRISPR / Cas9, stem cell biology, induced pluripotent stem cells, neurodegenerative disorders, Lysosomal Storage Disorders, anemia

Countries

Italy

Activities

Collapse all

Employment (5)

Università Vita-Salute San Raffaele Facoltà di Medicina e Chirurgia: Milano, Lombardia, IT

2022-12-20 to present | Ricercatore universitario a t.d.
Employment
Source: Self-asserted source
vasco meneghini

San Raffaele Hospital: Milan, IT

2019-07-01 to present | Project Leader (TIGET)
Employment
Source: Self-asserted source
vasco meneghini

institut imagine: Paris, FR

2014-09-01 to 2019-04-30 | Post-Doc
Employment
Source: Self-asserted source
vasco meneghini

Ospedale San Raffaele: Milano, Lombardia, IT

2011 to 2014 | Post-Doc (TIGET )
Employment
Source: Self-asserted source
vasco meneghini

Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze del Farmaco: Novara, Piemonte, IT

2010 to 2011 | Post-Doc
Employment
Source: Self-asserted source
vasco meneghini

Education and qualifications (3)

Università degli Studi del Piemonte Orientale Amedeo Avogadro Dipartimento di Scienze del Farmaco: Novara, Piemonte, IT

2006 to 2010 | PhD
Education
Source: Self-asserted source
vasco meneghini

Universita degli Studi di Milano-Bicocca: Milano, Lombardia, IT

2003 to 2006 | Master Degree (2nd level) in Industrial Biotechnology
Education
Source: Self-asserted source
vasco meneghini

Universita degli Studi di Milano-Bicocca: Milano, Lombardia, IT

1999 to 2003 | Degree (1st level) in Molecular Biotechnology
Education
Source: Self-asserted source
vasco meneghini

Professional activities (11)

International Society for Stem Cell Research: Skokie, IL, US

Membership
Source: Self-asserted source
vasco meneghini

European Society of Gene and Cell Therapy: Hannover, DE

Membership
Source: Self-asserted source
vasco meneghini

Frontiers Media SA: Lausanne, VD, CH

2021 to present | Review Editor on the Editorial Board of Molecular Diagnostics and Therapeutics
Invited position
Source: Self-asserted source
vasco meneghini

Frontiers Media SA: Lausanne, VD, CH

2020 to present | Review Editor on the Editorial Board of Neurodevelopment
Invited position
Source: Self-asserted source
vasco meneghini

Frontiers Media SA: Lausanne, VD, CH

2019-10-28 to present | Review Editor on the Editorial Board of Genome Editing in Blood Disorders
Invited position
Source: Self-asserted source
vasco meneghini

Society for Neuroscience: Washington, DC, US

2018-01-01 to present
Membership
Source: Self-asserted source
vasco meneghini

American Society of Gene Therapy and Cell Therapy: Milwaukee, Wisconsin, US

2017-01-01 to present
Membership
Source: Self-asserted source
vasco meneghini

Frontiers Media SA: Lausanne, VD, CH

2022 | Associate Editor at Genome Engineering and Neurologic Disorders
Distinction
Source: Self-asserted source
vasco meneghini

American Society of Gene & Cell Therapy: Waukesha, WI, US

2021-05 | Travel Grant - 24th Annual Meeting
Distinction
Source: Self-asserted source
vasco meneghini

American Society of Gene Therapy and Cell Therapy: Milwaukee, Wisconsin, US

2018-05-01 | Outstanding Poster Presentation - 21th Annual Meeting
Distinction
Source: Self-asserted source
vasco meneghini

American Society of Gene & Cell Therapy: Waukesha, WI, US

2017-05-01 | Oustanding Poster Presentation - 20th Annual Meeting
Distinction
Source: Self-asserted source
vasco meneghini

Funding (4)

Identification of clinically relevant hiPSC-derived neural stem cell populations for cell therapies of neurodegenerative disorders

2019-09 to present | Award
10x Genomics (Leiden, NL)
Source: Self-asserted source
vasco meneghini

Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease

2017-04 to 2019-04 | Contract
SATT IDF Innov (Paris, FR)
Source: Self-asserted source
vasco meneghini

hiPSC-based platform to optimize CRISPR/Cas9-mediated genome editing approaches in sickle cell disease

2015-12 to 2016-12 | Salary award
Campus France (Paris, FR)
GRANT_NUMBER:

PRESTIGE-2015-2-0015
Source: Self-asserted source
vasco meneghini

Gene therapy for Methachromatic Leukodystrophy

2011-07 to 2012-07 | Contract
Fondazione Telethon (Rome, IT)
Source: Self-asserted source
vasco meneghini

Peer review (1 review for 1 publication/grant)

Review activity for Reviews in endocrine and metabolic disorders. (1)
How many people are using ORCID?